Nonadherence to GLP-1 Receptor Agonists Among Individuals With Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Understanding why people stop taking GLP-1 drugs helps identify practical strategies to keep patients on these obesity treatments longer.
This meta-analysis of randomized controlled trials provides the first comprehensive quantification of nonadherence to GLP-1 receptor agonists in overweight/obese individuals, pooling data across major trials. The findings directly inform clinical strategies for improving real-world outcomes with semaglutide, liraglutide, and related agents in the context of the global obesity epidemic.
What the study was
- Study design
- Systematic review and meta-analysis of RCTs
- Population
- Individuals with overweight or obesity enrolled in GLP-1 RA RCTs
- Category
- Public Health
- Maturity
- Validated
- Journal
- Obesity reviews
Why it surfaced
GLP-1 RAs are among the most widely prescribed drugs globally. Meta-analysis of adherence from RCT data (highest quality adherence evidence) has immediate clinical utility for optimizing therapy and informing prescribing strategies.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.